VIAGRA Drug Patent Profile

When do Viagra patents expire, and what generic alternatives are available?

Viagra is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in VIAGRA is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viagra

A generic version of VIAGRA was approved as sildenafil citrate by CHARTWELL RX on November 6^th, 2012.

Summary for VIAGRA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIAGRA

Paragraph IV (Patent) Challenges for VIAGRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIAGRA	Tablets	sildenafil citrate	25 mg and 50 mg	020895	1	2004-11-19
VIAGRA	Tablets	sildenafil citrate	100 mg	020895	1	2004-10-25

US Patents and Regulatory Information for VIAGRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-001	Mar 27, 1998	AB	RX	Yes	No
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-002	Mar 27, 1998	AB	RX	Yes	No
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-003	Mar 27, 1998	AB	RX	Yes	Yes

International Patents for VIAGRA

See the table below for patents covering VIAGRA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	163852
European Patent Office	0463756	Pyrazolopyrimidones comme agents antiangineux. (Pyrazolopyrimidinone antianginal agents.)
Poland	311948

Supplementary Protection Certificates for VIAGRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	C990005	Netherlands		PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	99C0007	Belgium		PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	5/1999	Austria		PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622

Summary

Last updated: February 3, 2026

Viagra (sildenafil citrate) remains a blockbuster drug with mature market dynamics. Its revenue generation depends heavily on patent protection, competition from generics, regulatory environment, and global cardiovascular and erectile dysfunction (ED) treatment trends. Analyzing its investment viability requires considering patent cliffs, off-label uses, emerging competitors, and regulatory risks.

---

What Are the Historical Sales and Market Position of Viagra?

Viagra, developed by Pfizer, generated peak annual revenues of approximately $2.1 billion in 2012.[1] Since patent expiration in key markets, sales have declined due to generic competition. Still, it retains a significant market share, especially in certain regions and formulations.

Sales Trends Post-Patent Expiry:

• 2013-2016: Generic versions entered U.S. and European markets, causing revenue declines of over 80%.[2]
• 2017-2022: Sales stabilized in some regions driven by formulations like Viagra Connect (over-the-counter in the UK), and off-label uses.
• 2023: Estimated global sales stand around $250-300 million, mainly from Europe and emerging markets.[3]

---

What Are the Patents and Regulatory Status?

Pfizer held the U.S. patent for Viagra until 2013.[4] International patents lapsed earlier in many jurisdictions. Generic manufacturers introduced sildenafil citrate formulations post-patent expiry, eroding Pfizer’s market share.

Regulatory approval in multiple jurisdictions remains, with some markets approving over-the-counter (OTC) versions, such as in the UK (Viagra Connect). These OTC licenses can create new revenue channels but also introduce competition from unregulated sources.

Patent and Regulatory Highlights:

• Patent expiration in the U.S.: December 2013.
• European patents expired earlier in most EU countries (2012-2013).
• OTC approval: UK (2018), with ongoing discussions in others.
• Regulatory hurdles for new formulations or indications remain significant, requiring extensive trials.

---

What Are the Main Competitive Factors?

The primary competition for Viagra includes:

• Generic Sildenafil: Lower-cost alternatives dominate the market post-patent expiry.
• Other ED Drugs: Cialis (tadalafil) and Levitra (vardenafil) maintain market share with longer-lasting effects.
• Emerging Therapies: Non-pharmacological options and gene therapies are under development but are not yet mainstream.
• Over-the-Counter Availability: Encourages self-medication but can dilute Pfizer’s premium pricing.

Market Share Data:

As of 2022, generics accounted for approximately 80-85% of sildenafil sales globally, with Pfizer’s sales confined mostly to branded or premium formulations in regions where generics are less accessible.

---

What Are the Key Market Risks and Future Opportunities?

Risks:

• Patent expiration eliminated exclusive manufacturing rights in most jurisdictions.
• Price competition reduces profit margins.
• Regulatory restrictions on OTC sales or off-label indications.
• Cultural and socio-economic barriers in emerging markets.

Opportunities:

• Reformulations targeting specific demographics.
• Expansion into hypertension and pulmonary arterial hypertension (PAH), where sildenafil has approved indications.
• Repurposing for novel therapeutic areas like heart failure or neurodegenerative diseases, currently under research.
• Growth in over-the-counter sales in select regions.

---

What Is the Investment Outlook for Viagra?

• Short-term: Limited growth prospects due to generic dominance; revenue mainly from legacy brands and niche markets.
• Medium-term: Potential gains from OTC formulations and new indications, but uncertain regulatory approval timelines.
• Long-term: The product’s revenue prospects depend on innovation, market penetration, and regulatory landscape changes.

Pfizer’s strategic moves, such as developing new formulations or expanding into alternative indications, influence valuation. Remaining competitive may involve investments in R&D, licensing, or strategic partnerships.

---

Key Takeaways

• Viagra’s peak sales occurred before patent expiry; current revenues are declining.
• Generic competition has significantly reduced market exclusivity.
• OTC formulations and new indications present growth avenues but face regulatory hurdles.
• Pfizer’s strategic shifts are critical to sustaining or increasing value derived from the drug.
• Market risks remain high due to commoditization, pricing pressure, and regulatory variability.

---

FAQs

1. How long will patents protect Viagra in major markets?
Patent protections in the U.S. expired in December 2013; other jurisdictions expired around 2012-2013, allowing generic competition.

2. Can Viagra regain market share from generics?
Unlikely directly. Strategies focus on differentiating formulations, expanding OTC access, and developing new indications for sustained revenue.

3. Are there any regulatory hurdles to OTC sales?
Yes. OTC approval depends on safety profiles and efficacy data, with some regions requiring robust clinical evidence for over-the-counter licensing.

4. What alternatives could threaten Viagra’s market?
Longer-acting ED drugs like Cialis and Levitra retain market presence. Future threats could include biologics or gene therapies for ED.

5. What is the potential of sildenafil in other therapeutic areas?
Sildenafil is approved for PAH and under investigation for heart failure and neurodegenerative diseases. These avenues could diversify revenue streams.

---

References

1. Pfizer Annual Reports 2012-2022.
2. IMS Health Data on Generic Sildenafil Market Penetration.
3. MarketWatch, 2023.
4. U.S. Patent No. 4,413,012, expiring 2013.